EGFR and non-small cell lung carcinoma: Of note, NSCLC cells with an EGFR mutation also respond well to 1,25(OH)2D3, and 1,25(OH)2D3/erlotinib combination increased erlotinib cytotoxicity in both the erlotinib-sensitive HCC827 cell line and the erlotinib-resistant H1975 cell line18.